{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-064145","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.874140+00:00","generated_at":"2026-05-18T14:35:37.626844+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025","bullets":["Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.","Independent DMC recommends continue study unchanged; no serious adverse events reported.","Faster enrollment means 90-day visit and CSF biomarker results earlier in Q4 2025 vs. Q1 2026.","Screening window extended through July 31, 2025; planning to request dosing extension beyond 90 days in Australia.","Long-term toxicology studies near completion; update on dosing extension expected before end of Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-064145","json":"https://secwatch.observer/filing/0001104659-25-064145.json","markdown":"https://secwatch.observer/filing/0001104659-25-064145.md","text":"https://secwatch.observer/filing/0001104659-25-064145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/0001104659-25-064145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/tm2518735d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:35:37.626844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}